Drug intelligence / Profile preview

mephedrone + methcathinone

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intranasal, Intravenous
01

Overview

Mephedrone + methcathinone is an illicit combination of two synthetic stimulant drugs from the cathinone chemical class. Mephedrone (4-methylmethcathinone) is known for its entactogenic and stimulant effects, acting as a non-selective monoamine uptake inhibitor and releaser at dopamine, serotonin, and norepinephrine transporters, with additional affinity for 5-HT2A and α-adrenergic receptors[1][2][3]. Methcathinone is a closely related stimulant, structurally similar to both mephedrone and cathinone itself, with primary action as a dopamine and norepinephrine releasing agent. The combination is used recreationally for its strong stimulant and empathogenic effects but carries elevated risks of harmful cardiovascular and neuropsychiatric effects, including increased risk of heart strain, serotonin syndrome, and seizures. Both substances are controlled in most jurisdictions, and their combination significantly increases the danger of acute toxicity[1][4].

Other names
4-methylmethcathinone + methcathinone4-MMC + MACCM-CAT + methcathinonemeow meow + methcathinonedrone + methcathinone
02

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)ADRA1 (Alpha-1 adrenergic receptor family)HTR2A (Serotonin receptor 5-HT2A)TAAR1 (Trace amine-associated receptor 1)

Beyond the preview

Go deeper on mephedrone + methcathinone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mephedrone + methcathinone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call